235 related articles for article (PubMed ID: 17944704)
1. In vitro susceptibilities of Aspergillus spp. causing otomycosis to amphotericin B, voriconazole and itraconazole.
Kaya AD; Kiraz N
Mycoses; 2007 Nov; 50(6):447-50. PubMed ID: 17944704
[TBL] [Abstract][Full Text] [Related]
2. A comparative study of the in vitro susceptibilities of clinical and laboratory-selected resistant isolates of Aspergillus spp. to amphotericin B, itraconazole, voriconazole and posaconazole (SCH 56592).
Manavathu EK; Cutright JL; Loebenberg D; Chandrasekar PH
J Antimicrob Chemother; 2000 Aug; 46(2):229-34. PubMed ID: 10933645
[TBL] [Abstract][Full Text] [Related]
3. Microdilution susceptibility testing of amphotericin B, itraconazole, and voriconazole against clinical isolates of Aspergillus and Fusarium species.
Arikan S; Lozano-Chiu M; Paetznick V; Nangia S; Rex JH
J Clin Microbiol; 1999 Dec; 37(12):3946-51. PubMed ID: 10565912
[TBL] [Abstract][Full Text] [Related]
4. In vitro susceptibilities of Aspergillus species to voriconazole, itraconazole, and amphotericin B.
Abraham OC; Manavathu EK; Cutright JL; Chandrasekar PH
Diagn Microbiol Infect Dis; 1999 Jan; 33(1):7-11. PubMed ID: 9990469
[TBL] [Abstract][Full Text] [Related]
5. In-vitro activity of voriconazole against Aspergillus spp. and comparison with itraconazole and amphotericin B.
Oakley KL; Moore CB; Denning DW
J Antimicrob Chemother; 1998 Jul; 42(1):91-4. PubMed ID: 9700534
[TBL] [Abstract][Full Text] [Related]
6. Use of spectrophotometric reading for in vitro antifungal susceptibility testing of Aspergillus spp.
Dannaoui E; Persat F; Monier MF; Borel E; Piens MA; Picot S
Can J Microbiol; 1999 Oct; 45(10):871-4. PubMed ID: 10907424
[TBL] [Abstract][Full Text] [Related]
7. In-vitro activities of amphotericin B, itraconazole and voriconazole against 150 clinical and environmental Aspergillus fumigatus isolates.
Verweij PE; Mensink M; Rijs AJ; Donnelly JP; Meis JF; Denning DW
J Antimicrob Chemother; 1998 Sep; 42(3):389-92. PubMed ID: 9786480
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the in-vitro activity of voriconazole (UK-109,496), itraconazole and amphotericin B against clinical isolates of Aspergillus fumigatus.
Cuenca-Estrella M; Rodríguez-Tudela JL; Mellado E; Martínez-Suárez JV; Monzón A
J Antimicrob Chemother; 1998 Oct; 42(4):531-3. PubMed ID: 9818755
[TBL] [Abstract][Full Text] [Related]
9. In vitro activity of a novel broad-spectrum antifungal, E1210, tested against Aspergillus spp. determined by CLSI and EUCAST broth microdilution methods.
Pfaller MA; Duncanson F; Messer SA; Moet GJ; Jones RN; Castanheira M
Antimicrob Agents Chemother; 2011 Nov; 55(11):5155-8. PubMed ID: 21844312
[TBL] [Abstract][Full Text] [Related]
10. In-vitro susceptibility of Aspergillus spp. isolates to amphotericin B and itraconazole.
Dannaoui E; Persat F; Monier MF; Borel E; Piens MA; Picot S
J Antimicrob Chemother; 1999 Oct; 44(4):553-5. PubMed ID: 10588320
[TBL] [Abstract][Full Text] [Related]
11. In vitro activity of voriconazole against yeasts, moulds and dermatophytes in comparison with fluconazole, amphotericin B and griseofulvin.
Wildfeuer A; Seidl HP; Paule I; Haberreiter A
Arzneimittelforschung; 1997 Nov; 47(11):1257-63. PubMed ID: 9428984
[TBL] [Abstract][Full Text] [Related]
12. In vitro amphotericin B resistance in clinical isolates of Aspergillus terreus, with a head-to-head comparison to voriconazole.
Sutton DA; Sanche SE; Revankar SG; Fothergill AW; Rinaldi MG
J Clin Microbiol; 1999 Jul; 37(7):2343-5. PubMed ID: 10364610
[TBL] [Abstract][Full Text] [Related]
13. Antifungal activity of a new triazole, voriconazole (UK-109,496), compared with three other antifungal agents tested against clinical isolates of filamentous fungi.
Marco F; Pfaller MA; Messer SA; Jones RN
Med Mycol; 1998 Dec; 36(6):433-6. PubMed ID: 10206756
[TBL] [Abstract][Full Text] [Related]
14. In-vitro activity of voriconazole, itraconazole and amphotericin B against filamentous fungi.
Johnson EM; Szekely A; Warnock DW
J Antimicrob Chemother; 1998 Dec; 42(6):741-5. PubMed ID: 10052897
[TBL] [Abstract][Full Text] [Related]
15. In vitro activity of the new triazole BMS-207147 against Aspergillus species in comparison with itraconazole and amphotericin B.
Moore CB; Walls CM; Denning DW
Antimicrob Agents Chemother; 2000 Feb; 44(2):441-3. PubMed ID: 10639380
[TBL] [Abstract][Full Text] [Related]
16. Molecular identification and antifungal susceptibility profile of Aspergillus flavus isolates recovered from clinical specimens in Kuwait.
Al-Wathiqi F; Ahmad S; Khan Z
BMC Infect Dis; 2013 Mar; 13():126. PubMed ID: 23496810
[TBL] [Abstract][Full Text] [Related]
17. Susceptibility of Aspergillus strains from culture collections to amphotericin B and itraconazole.
Rath PM
J Antimicrob Chemother; 1998 May; 41(5):567-70. PubMed ID: 9630411
[TBL] [Abstract][Full Text] [Related]
18. In vitro evaluation of voriconazole against clinical isolates of yeasts, moulds and dermatophytes in comparison with itraconazole, ketoconazole, amphotericin B and griseofulvin.
Wildfeuer A; Seidl HP; Paule I; Haberreiter A
Mycoses; 1998; 41(7-8):309-19. PubMed ID: 9861837
[TBL] [Abstract][Full Text] [Related]
19. Organism-dependent fungicidal activities of azoles.
Manavathu EK; Cutright JL; Chandrasekar PH
Antimicrob Agents Chemother; 1998 Nov; 42(11):3018-21. PubMed ID: 9797246
[TBL] [Abstract][Full Text] [Related]
20. In vitro activity of voriconazole against selected fungi.
McGinnis MR; Pasarell L; Sutton DA; Fothergill AW; Cooper CR; Rinaldi MG
Med Mycol; 1998 Aug; 36(4):239-42. PubMed ID: 9776841
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]